公开(公告)号：US20190351098A1

公开(公告)日：2019-11-21

申请号：US16480114

申请日：2018-01-31

Applicant: TOPPAN PRINTING CO., LTD. ,  OSAKA UNIVERSITY

Inventor： Michiya MATSUSAKI ,  Shinji IRIE ,  Shiro KITANO

IPC: A61L27/24 ,  C12N5/00 ,  A61L31/04 ,  A61L27/44 ,  A61L27/54

Abstract: Disclosed is a three-dimensional tissue comprising cells and collagen including endogenous collagen, wherein at least a portion of the cells is adhered to the collagen, and the content of the collagen is from 10 wt % to 90 wt % based on the three-dimensional tissue.

公开(公告)号：US20190049431A1

公开(公告)日：2019-02-14

申请号：US16164914

申请日：2018-10-19

Applicant: TOPPAN PRINTING CO., LTD.

Inventor： Shiro KITANO ,  Kei Tsukamoto ,  Shinji Irie

IPC: G01N33/50

Abstract: A method of producing drug resistant cells including contacting exosomes from a living organism exhibiting drug resistance with cells exhibiting no drug resistance such that drug resistant cells are formed, and culturing the drug resistant cells.

公开(公告)号：US20210238542A1

公开(公告)日：2021-08-05

申请号：US17050731

申请日：2019-05-07

Applicant: TOPPAN PRINTING CO., LTD. ,  OSAKA UNIVERSITY

Inventor： Shiro KITANO ,  Shinji IRIE ,  Michiya MATSUSAKI

IPC: C12N5/00

Abstract: The present invention relates to an extracellular-matrix-containing composition comprising: a fragmented extracellular matrix component, wherein at least a part of the fragmented extracellular matrix component is crosslinked.

公开(公告)号：US20180112260A1

公开(公告)日：2018-04-26

申请号：US15821373

申请日：2017-11-22

Applicant: TOPPAN PRINTING CO., LTD. ,  TOKYO INSTITUTE OF TECHNOLOGY

Inventor： Shiro KITANO ,  Atsushi MARUYAMA ,  Naohiko SHIMADA

IPC: C12Q1/6832 ,  C12Q1/6869 ,  C12Q1/6827 ,  C08B37/02 ,  C08G73/02

CPC classification number: C12Q1/6832 ,  C08B37/0021 ,  C08G73/02 ,  C12N15/09 ,  C12Q1/25 ,  C12Q1/68 ,  C12Q1/6823 ,  C12Q1/6827 ,  C12Q1/6869 ,  G01N33/50 ,  G01N33/53 ,  C12Q2521/345 ,  C12Q2527/125

Abstract: The present invention relates to a method for detecting a target nucleic acid using a catalytic nucleic acid, which can improve the reaction efficiency of a catalytic nucleic acid and achieve continuous reaction under isothermal conditions. The method for detecting a target nucleic acid includes a reaction step to obtain a first nucleic acid product by hybridizing a first nucleic acid which is a substrate to a first binding site of a catalytic nucleic acid equipped with an active site having a catalytic action; and a detection step for detecting at least one of the first nucleic acid product or unreacted first nucleic acids, wherein, the hybridization is carried out in the presence of a cationic comb-type polymer.

公开(公告)号：US20170002425A1

公开(公告)日：2017-01-05

申请号：US15153240

申请日：2016-05-12

Applicant: TOPPAN PRINTING CO., LTD.

Inventor： Shiro KITANO ,  Takeshi YAMADA

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57419 ,  G01N2333/475 ,  G01N2333/515 ,  G01N2800/52 ,  G01N2800/7014

Abstract: A method for predicting long-term efficacy of a VEGF inhibitor of the present invention includes determining whether or not an RAS gene-derived nucleic acid or an RAS protein is present in a blood sample collected from a subject, determines whether the RAS gene-derived nucleic acid in the blood sample is a wild type or a mutant or whether the RAS protein in the blood sample is a wild type or a mutant, determining that an antitumor effect resulting from the VEGF inhibitor is highly likely to last for a long period of time in the subject in a case where a wild-type RAS gene-derived nucleic acid or a wild-type RAS protein is detected in the blood sample and a mutant RAS gene-derived nucleic acid or a mutant RAS protein is not detected in the blood sample.

Abstract translation: 用于预测本发明的VEGF抑制剂的长期功效的方法包括确定RAS基因衍生的核酸或RAS蛋白是否存在于从受试者收集的血液样品中，确定RAS基因衍生的 血液样品中的核酸是野生型或突变体，或血液样品中的RAS蛋白是野生型还是突变体，确定由VEGF抑制剂产生的抗肿瘤作用很可能长时间持续 在血液样本中检测到野生型RAS基因衍生的核酸或野生型RAS蛋白质的情况下，在未检测到突变体RAS基因的核酸或突变型RAS蛋白质的情况下， 血液样本。